Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In db/db mice, CK treatment increases secondary BAs, such as lithocholic acid (LCA) and deoxycholic acid (DCA) through changes in the gut microbiota, especially the Ruminococcaceae family, and up-regulation of cytochrome P450 family 7 subfamily B member 1 ( Cyp7b1 ) and cytochrome P450 family 27 subfamily A member 1 ( Cyp27a1 ) and down-regulation of cytochrome P450 family 8 subfamily B member 1 ( Cyp8b1 ), which changes BA biosynthesis from the classical pathway to the alternative pathway
Recurring themes that surface repeatedly include: Local vs systemic is the central talking point
Published safety data comes entirely from animal studies, which show excellent tolerability with no reported serious adverse events
Treatment may include fasting, IV fluids and antibiotics
Ageing research reviews, 92, 102066
doi: 10.3389/FIMMU.2023.1194923 85 JaroszK.StadnikD
